Target type: biologicalprocess
Any process that stops, prevents or reduces the frequency, rate or extent of cytoplasmic translation. [GOC:obol]
Negative regulation of cytoplasmic translation is a complex process that involves a variety of mechanisms to control the rate of protein synthesis in the cytoplasm. This regulation is crucial for maintaining cellular homeostasis, responding to environmental changes, and controlling cell growth and differentiation. Here’s a detailed breakdown of the key mechanisms involved:
1. **Regulation at the Initiation Stage:**
- **eIF2 Phosphorylation:** The eukaryotic initiation factor 2 (eIF2) is a key regulator of translation initiation. When eIF2 is phosphorylated, it binds to the guanine nucleotide exchange factor eIF2B, inhibiting its activity. This results in reduced formation of the ternary complex (eIF2-GTP-methionine tRNA), which is essential for initiating translation. Phosphorylation of eIF2 can be triggered by various stress signals, including nutrient deprivation, viral infection, and unfolded protein stress.
- **mTOR Signaling Pathway:** The mechanistic target of rapamycin (mTOR) is a central regulator of cell growth and metabolism. mTOR activation promotes protein synthesis by stimulating the phosphorylation of eIF2B, leading to increased formation of the ternary complex and enhanced translation initiation.
2. **Regulation at the Elongation Stage:**
- **Ribosome Stalling:** Ribosomes can stall during translation elongation due to various factors, such as the presence of rare codons or secondary structures in mRNA. This stalling can trigger quality control mechanisms that lead to ribosome recycling or mRNA degradation.
- **Regulation by MicroRNAs (miRNAs):** miRNAs are small non-coding RNAs that can bind to target mRNAs and inhibit their translation. By targeting specific mRNAs, miRNAs can fine-tune protein expression and contribute to the negative regulation of translation.
3. **Regulation at the Termination Stage:**
- **Release Factors (RFs):** Release factors (RF1 and RF2) recognize stop codons in mRNA and trigger the release of the polypeptide chain from the ribosome. This process is essential for terminating translation.
4. **Other Mechanisms:**
- **mRNA Degradation:** The stability of mRNAs can be regulated, and degradation of mRNAs can lead to a decrease in protein synthesis.
- **Translational Repression by RNA-binding Proteins:** Specific RNA-binding proteins can bind to mRNAs and repress their translation. These proteins often recognize specific sequences or structures in mRNAs and can act as translation repressors.
In summary, negative regulation of cytoplasmic translation is a multi-layered process involving control at various steps of translation initiation, elongation, and termination. These regulatory mechanisms are essential for maintaining cellular homeostasis, responding to environmental changes, and controlling cell growth and differentiation.'
"
Protein | Definition | Taxonomy |
---|---|---|
50S ribosomal protein L4 | A large ribosomal subunit protein uL4 that is encoded in the genome of Escherichia coli K-12. [PRO:DNx, UniProtKB:P60723] | Escherichia coli K-12 |
30S ribosomal protein S1 | A small ribosomal subunit protein bS1 that is encoded in the genome of Escherichia coli K-12. [PRO:DNx, UniProtKB:P0AG67] | Escherichia coli K-12 |
Protein mono-ADP-ribosyltransferase PARP16 | A protein mono-ADP-ribosyltransferase PARP16 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8N5Y8] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
chloramphenicol | Amphenicol: Chloramphenicol and its derivatives. | C-nitro compound; carboxamide; diol; organochlorine compound | antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor |
framycetin | framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B. Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed) | aminoglycoside | allergen; antibacterial drug; Escherichia coli metabolite |
erythromycin | erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus). erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. | cyclic ketone; erythromycin | |
neamine | neamine : 2-Deoxy-D-streptamine glycosylated at the 4-oxygen with a 6-amino-alpha-D-glucosaminyl group. neamine: fragment of NEOMYCIN B; structure in first source | 2,6-dideoxy-alpha-D-glucoside; aminoglycoside | antibacterial agent |
4-Methoxybenzamide | benzamides | ||
florfenicol | florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture. florfenicol: structure given in first source | organochlorine compound; organofluorine compound; secondary alcohol; secondary carboxamide; sulfone | antimicrobial agent |
antibiotic g 418 | antibiotic G 418: from Micromonospora rhodorangea | ||
paromomycin | paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis. Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES. | amino cyclitol glycoside; aminoglycoside antibiotic | anthelminthic drug; antibacterial drug; antiparasitic agent; antiprotozoal drug |
puromycin | puromycins | antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor | |
netilmicin | Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. | ||
linezolid | acetamides; morpholines; organofluorine compound; oxazolidinone | antibacterial drug; protein synthesis inhibitor | |
zithromax | azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections. Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis. | macrolide antibiotic | antibacterial drug; environmental contaminant; xenobiotic |
tiamulin | tiamulin : A carbotricyclic compound that is pleuromutilin in which the hydroxyacetate group is replaced by a 2-{[2-(diethylamino)ethyl]sulfanyl}acetate group. An antibacterial drug, tiamulin is used in veterinary medicine (generally as its hydrogen fumarate salt) for the treatment of swine dysentery caused by Serpulina hyodysenteriae. tiamulin: 81723 HFU and tiamutin are for fumarate salt; prevents senescence in ascomycete; pleuromutilin derivative; RN given refers to ((3aS-(3aalpha,4beta,5alpha,6alpha,8beta,9alpha,9abeta,10S*))-isomer | carbotricyclic compound; carboxylic ester; cyclic ketone; organic sulfide; secondary alcohol; semisynthetic derivative; tertiary amino compound; tetracyclic diterpenoid | antibacterial drug |
hmr 3647 | |||
josamycin | acetate ester; aldehyde; disaccharide derivative; glycoside; macrolide antibiotic; tertiary alcohol; tertiary amino compound | antibacterial drug; metabolite | |
albocycline | albocycline: macrolide antibiotic isolated from Streptomyces bruneogriseus nov. sp. MCRL-0129; specifically anti-staphylococcal, including antibiotic-resistant strains; structure | macrolide | |
evernimicin | |||
gentamicin sulfate | |||
rucaparib | AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source | azepinoindole; caprolactams; organofluorine compound; secondary amino compound | antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor |
latonduine a | latonduine A: structure in first source | ||
pristinamycin iib | virginiamycin M2: structure in first source | ||
veliparib | benzimidazoles | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
olaparib | cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
niraparib | niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy. niraparib: structure in first source | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent |
cem 101 | solithromycin: an antibacterial fluoroketolide; structure in first source | ||
tetracycline | tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria. Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis. | ||
eravacycline | eravacycline: has antibacterial activity | tetracyclines | |
xav939 | XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group. XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source | (trifluoromethyl)benzenes; thiopyranopyrimidine | tankyrase inhibitor |
bmn 673 | talazoparib: inhibits both PARP1 and PARP2; structure in first source |